Health & Biotech
Paradigm makes key submission to US FDA to advance osteoarthritis Phase 3 trial
ASX Health Stocks: Paradigm responds to US FDA, seeks marketing approval from TGA
ASX Health Stocks: Immutep hooks leading research firm CHDR to conduct Phase 1 drug study
PharmAust bolsters manufacturing leadership to expand path to commercialisation
Which ASX companies are resurrecting abandoned drugs? Part 3
Weed Week: A VAST majority of Americans now want marijuana to be legal
Neurotech’s Phase 2/3 autism trial meets primary endpoint
Neurotech reports positive top-line Phase 1/2 Rett Syndrome clinical trial results
ASX Health Stocks: Firebrick skyrockets 80pc on Nasodine’s US launch
Melodiol unaudited revenue up 79% in Q1 FY24
Which ASX companies are resurrecting abandoned drugs? Part 2
ASX Health Stocks: Island Pharma releases data on dengue fever drug, IDT signs $3m+ deal with Sanofi
Bioxyne subsidiary granted upgraded wholesale licence for MDMA and psilocybin finished products
Which ASX companies are resurrecting abandoned drugs? Part 1
ASX Health Stocks: Atomo sells more HIV Self-Tests; Actinogen begins Phase 2b trial on Alzheimer’s
ASX Health Stocks: GTG to establish pilot program in US using its geneType Breast Cancer Risk Test
PharmAust inks approval from Macquarie University for Open-Label MND extension study
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.